Amgen Inc. $AMGN Shares Sold by StoneX Group Inc.

Key Points

• StoneX Group cut its Amgen stake by 74% in the third quarter, selling 9,192 shares and retaining 3,224 shares valued at about $1.36 million.
• Amgen reported quarterly earnings of $6.45 per share, above the $5.79 analyst consensus, while revenue of $10.37 billion rose 8.5% year over year and also topped estimates.
• Amgen declared a quarterly dividend of $2.52 per share, equivalent to an annualized yield of about 2.2%; analysts’ consensus rating was Hold, with an average price target of $422.76.

StoneX Group Inc. lowered its position in shares of Amgen Inc. (NASDAQ:AMGN - Free Report) by 74.0% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 3,224 shares of the medical research company's stock after selling 9,192 shares during the quarter. StoneX Group Inc.'s holdings in Amgen were worth $1,360,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also bought and sold shares of AMGN. State Street Corp grew its holdings in shares of Amgen by 38.2% in the second quarter. State Street Corp now owns 42,205,243 shares of the medical research company's stock valued at $15,283,363,000 after purchasing an additional 11,656,755 shares in the last quarter. MW Advisory LLC bought a new stake in Amgen in the second quarter worth $1,054,000. Baird Financial Group Inc. increased its position in Amgen by 1.6% in the second quarter. Baird Financial Group Inc. now owns 339,825 shares of the medical research company's stock worth $123,057,000 after purchasing an additional 5,496 shares during the last quarter. MassMutual Private Wealth & Trust FSB raised its stake in Amgen by 105.8% during the third quarter. MassMutual Private Wealth & Trust FSB now owns 13,514 shares of the medical research company's stock valued at $5,696,000 after purchasing an additional 6,947 shares in the last quarter. Finally, Nilsine Partners LLC purchased a new stake in Amgen during the second quarter valued at $3,329,000. 76.50% of the stock is owned by institutional investors.

Insider Transactions at Amgen

In other Amgen news, SVP Rachna Khosla sold 1,252 shares of the business's stock in a transaction that occurred on Thursday, August 13th. The stock was sold at an average price of $416.43, for a total transaction of $521,370.36. Following the completion of the transaction, the senior vice president owned 6,404 shares in the company, valued at $2,666,817.72. The trade was a 16.35% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 0.85% of the stock is currently owned by insiders.

Amgen Trading Up 1.0%

AMGN stock opened at $465.23 on Tuesday. Amgen Inc. has a twelve month low of $312.39 and a twelve month high of $483.99. The stock has a market capitalization of $251.52 billion, a price-to-earnings ratio of 26.99, a price-to-earnings-growth ratio of 3.47 and a beta of 0.43. The company has a quick ratio of 1.13, a current ratio of 1.48 and a debt-to-equity ratio of 3.60. The firm's fifty day simple moving average is $423.08 and its two-hundred day simple moving average is $378.80.

Amgen (NASDAQ:AMGN - Get Free Report) last released its earnings results on Tuesday, November 3rd. The medical research company reported $6.45 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.79 by $0.66. Amgen had a net margin of 24.14% and a return on equity of 114.99%. The firm had revenue of $10.37 billion during the quarter, compared to analyst estimates of $10.07 billion. During the same quarter last year, the business earned $5.64 EPS. The business's revenue was up 8.5% on a year-over-year basis. As a group, analysts anticipate that Amgen Inc. will post 23.33 earnings per share for the current year.

Amgen Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, December 11th. Shareholders of record on Friday, November 20th will be paid a $2.52 dividend. The ex-dividend date of this dividend is Friday, November 20th. This represents a $10.08 annualized dividend and a yield of 2.2%. Amgen's dividend payout ratio (DPR) is presently 58.47%.

Analyst Ratings Changes

AMGN has been the topic of a number of research reports. Truist Financial boosted their target price on shares of Amgen from $380.00 to $398.00 and gave the stock a "hold" rating in a report on Wednesday, November 4th. Weiss Ratings upgraded shares of Amgen from a "buy (b)" rating to a "buy (b+)" rating in a research report on Thursday, October 8th. Robert W. Baird increased their price target on shares of Amgen from $215.00 to $230.00 and gave the company an "underperform" rating in a report on Wednesday, August 5th. The Goldman Sachs Group lifted their price target on Amgen from $481.00 to $536.00 and gave the stock a "buy" rating in a research report on Wednesday, November 4th. Finally, Wall Street Zen upgraded Amgen from a "hold" rating to a "buy" rating in a research report on Sunday, October 18th. One investment analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating, eighteen have given a Hold rating and three have issued a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of "Hold" and a consensus target price of $422.76.

Trending Headlines about Amgen

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: New AHA 2026 data reinforced Repatha’s potential: an analysis found it cost-effective for high-risk patients without a prior heart attack or stroke, while a separate long-term analysis associated treatment with a 29% lower risk of major cardiovascular events in patients with ASCVD. The findings could support wider use, though the reported analyses do not guarantee future sales growth. Article: New Repatha data at AHA 2026
• Positive Sentiment: Amgen is heading into ACR week with a dazodalibep update expected November 11, creating a near-term clinical catalyst for its pipeline. The article headline does not specify the results, so the update’s impact will depend on the data. Article: Amgen stock heads into ACR week with dazodalibep update
• Positive Sentiment: An article highlighted experimental obesity drug MariTide’s potential to reduce dosing from 52 injections a year to four. If borne out in clinical development, less frequent dosing could be a competitive advantage; the drug remains experimental. Article: Amgen's new drug could mean fewer shots for obesity patients
• Neutral Sentiment: Amgen shares rose in Monday trading but underperformed the broader market, indicating the move was not as strong as the overall market’s. Article: Amgen stock rises Monday, still underperforms market
• Negative Sentiment: ETFs were net sellers of $68.5 million of AMGN on November 5, a potential near-term supply headwind, although 51 funds bought shares and 20 sold. Article: ETFs are net sellers of Amgen

Amgen Company Profile

Amgen is a biotechnology company that discovers, develops, manufactures and commercializes medicines for serious illnesses. Its research and product portfolio span areas including cancer, cardiovascular disease, inflammation, bone health and rare diseases.

The company's medicines include Enbrel, Prolia, Xgeva and Repatha. Amgen serves patients and healthcare providers in the United States and markets its products internationally.

Founded in 1980 and headquartered in Thousand Oaks, California, Amgen is led by Robert A.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.